Enhanced Vaccine Delivery Systems for Necrotic Enteritis Prevention in Poultry

This inventive concept discloses improved vaccine delivery systems for protecting poultry against necrotic enteritis, enhancing immunogenicity, reducing production costs, and increasing large-scale manufacturing efficiency.

The original patent for a vaccine against necrotic enteritis in poultry has limitations in terms of delivery, immunogenicity, and production costs. The present inventive concept addresses these limitations by introducing novel oral delivery systems, booster doses, and large-scale production methods that improve the overall efficiency and effectiveness of the vaccine.

The inventive concept comprises four main aspects: 1) a system for oral delivery of a necrotic enteritis vaccine using a plant-based expression system, 2) a method for boosting immune response against necrotic enteritis by administering a booster dose with a toll-like receptor agonist, 3) a vaccine composition with a beta-glucan adjuvant to enhance the humoral immune response, and 4) a system for large-scale production of the vaccine using a plant-based expression system and membrane filtration. These aspects work together to provide a more efficient, cost-effective, and immunogenic vaccine against necrotic enteritis.

The new claims introduce novel oral delivery systems, booster doses, and large-scale production methods that are not obvious from the original patent. The use of plant-based expression systems, toll-like receptor agonists, and beta-glucan adjuvants, as well as the specific combinations and formulations disclosed, provide a non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept could include different plant-based expression systems, various mucosal adjuvants, or alternative downstream processing methods. Variations could also include different formulations of the vaccine composition or different schedules for administering the booster dose.

The inventive concept has significant commercial potential in the poultry industry, where necrotic enteritis is a major concern. The improved vaccine delivery systems and production methods could lead to increased adoption and reduced costs, making the vaccine more accessible to poultry farmers worldwide.